Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 13 of 13 publications.

Grivas P, Barata P, Moon H, Gupta S, Hutson T, Sternberg CN, Brown JR, Dave V, Downey C, Shillington AC, Katzenstein HM, Kirker M, Hanson S, Liu FX, Morris V, Bhanegaonkar A, Sonpavde GP. Avelumab first-line maintenance for locally advanced or metastatic urothelial carcinoma: results from the Real-world US PATRIOT-II Study. Clin Genitourin Cancer. 2024 Dec;22(6):102238. doi: 10.1016/j.clgc.2024.102238

Esterberg E, Iyer S, Nagar SP, Davis KL, Tannir NM. Real-world treatment patterns and clinical outcomes among patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2024 Apr;22(2):115-125.e. doi: 10.1016/j.clgc.2023.09.009

Bellmunt J, Chang J, Pavilack-Kirker M, Cappelleri JC, Costa N, Esterberg E, Kearney M, Hitchens A, Candrilli SD, Ajmera M. Evaluating real-world characteristics of patients with advanced urothelial carcinoma eligible for avelumab maintenance therapy: a multi-country retrospective medical chart review. Clin Genitourin Cancer. 2023 Aug;21(4):459-66. doi: 10.1016/j.clgc.2023.03.011

Stattin P, Westerberg M, Franck Lissbrant I, Hjalm-Eriksson M, Kjellman A, Ullen A, Vassilev Z, Sandstrom P, Weinrib R, Martinez D, Garcia de Albeniz Martinez X. Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden. Clin Genitourin Cancer. 2022 Sep 9;S1558-7673(22):00194-X. doi: 10.1016/j.clgc.2022.09.002

Price KJ, Knowles JA, Fox M, Wales JK, Heller S, Eiser C, Freeman JV, Brennan A, Basarir H, Stevens K, McPherson A. Effectiveness of the Kids in Control of Food (KICk–OFF) structured education course for 11–16 year olds with type 1 diabetes. Diabet Med. 2016 Feb;33(2):192-203. doi: 10.1111/dme.12881

Wolowacz S, Pearson I, Shannon P, Chubb B, Gundgaard J, Davies M, Briggs A. Development and validation of a cost-utility model for Type 1 diabetes mellitus. Diabet Med. 2015 Aug;32(8):1023-35. doi: 10.1111/dme.12663

Thokala P, Kruger J, Brennan A, Basarir H, Duenas A, Pandor A, Gillett M, Elliott J, Heller S. Assessing the cost‐effectiveness of type 1 diabetes interventions: the Sheffield type 1 diabetes policy model. Diabet Med. 2014 Apr;31(4):477-86. doi: 10.1111/dme.12371

Fleming A, Philip S, Prescott G, Olson J, Sharp P. Presence of retinopathy and a high microaneurysm count increase the risk of subsequent cardiovascular disease. Poster presented at the Diabetes UK professional conference 2014; March 5, 2014. Liverpool, UK. [abstract] Diabet Med. 2014 Mar 1; 31(S1):86-7. doi: 10.1111/dme.12378_2

Davis AE, Mehrotra S, Friedewald J, Ladner D. Characteristics of a simulation model of the national kidney transplantation system. Poster presented at the 2013 Winter Simulation Conference: Simulation: Making Decisions in a Complex World; December 2013. [abstract] Ieee/Acm Trans Comput Biol Bioinform. 2013 Dec; p.2320-9.

Kruger J, Brennan A, Thokala P, Basarir H, Jacques R, Elliott J, Heller S, Speight J. The cost-effectiveness of 5-week versus 1-week DAFNE structured education in type 1 diabetes: a preliminary evaluation using the Sheffield type 1 diabetes policy model. Diabet Med. 2013 Oct;30(10):1236-44. doi: 10.1111/dme.1227

Hess G, Borker R, Fonseca E. Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting. Clin Genitourin Cancer. 2013 Jun;11(2):161-7. doi: 10.1016/j.clgc.2012.10.003

Goatman KA, Philip S, Fleming AD, Harvey RD, Swa KK, Styles C, Black M, Sell G, Lee N, Sharp PF, Olson JA. External quality assurance for image grading in the Scottish diabetic retinopathy screening programme. Diabet Med. 2012 Jun 1;29(6):776-83. doi: 10.1111/j.1464-5491.2011.03504.x

Nielsen GL, Norgard B, Puho E, Rothman KJ, Sorensen HT, Czeizel AE. Risk of specific congenital abnormalities in offspring of women with diabetes. Diabet Med. 2005 Jan 1;22(6):693-6.